FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415863453> ?p ?o ?g. }

• W2415863453 endingPage "e0156667" @default.
• W2415863453 startingPage "e0156667" @default.
• W2415863453 abstract "Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients with HBeAg positive chronic HBV infection. The REP 101 study examined REP 2055 monotherapy in 8 patients and the REP 102 study examined REP 2139-Ca, in monotherapy in 12 patients, 9 of which transitioned to short term combined treatment with pegylated interferon alpha 2a or thymosin alpha 1. In both studies NAP monotherapy was accompanied by 2–7 log reductions of serum HBsAg, 3–9 log reductions in serum HBV DNA and the appearance of serum anti-HBsAg antibodies (10–1712 mIU / ml). Eight of the 9 patients transitioning to combined treatment with immunotherapy (pegylated interferon or thymosin alpha 1) in the REP 102 study experienced HBsAg loss and all 9 patients experienced substantial increases in serum anti-HBsAg antibody titers before withdrawal of therapy. For 52 weeks after removal of REP 2055 therapy, rebound of serum viremia (HBV DNA > 1000 copies / ml, HBsAg > 1IU / ml) was not observed in 3 / 8 patients. Suppression of serum virema was further maintained for 290 and 231 weeks in 2 of these patients. After withdrawal of all therapy in the 9 patients that transitioned to combination therapy in the REP 102 study, 8 patients achieved HBV DNA < 116 copies / ml after treatment withdrawal. Viral rebound occurred over a period of 12 to 123 weeks in 7 patients but was still absent in two patients at 135 and 137 weeks of follow-up. Administration tolerability issues observed with REP 2055 were rare with REP 2139-Ca but REP 2139-Ca therapy was accompanied by hair loss, dysphagia and dysgeusia which were considered related to heavy metal exposure endemic at the trial site. These preliminary studies suggest that NAP can elicit important antiviral responses during treatment which may improve the effect of immunotherapy. NAPs may be a potentially useful component of future combination therapies for the treatment of chronic hepatitis B. Trial Registration: ClinicalTrials.gov NCT02646163 and NCT02646189" @default.
• W2415863453 created "2016-06-24" @default.
• W2415863453 creator A5026252641 @default.
• W2415863453 creator A5041530006 @default.
• W2415863453 creator A5054187794 @default.
• W2415863453 date "2016-06-03" @default.
• W2415863453 modified "2023-10-18" @default.
• W2415863453 title "Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection" @default.
• W2415863453 cites W1799522345 @default.
• W2415863453 cites W1967083475 @default.
• W2415863453 cites W1967462654 @default.
• W2415863453 cites W1977642707 @default.
• W2415863453 cites W1985860298 @default.
• W2415863453 cites W2009625082 @default.
• W2415863453 cites W2018230230 @default.
• W2415863453 cites W2020368715 @default.
• W2415863453 cites W2037862975 @default.
• W2415863453 cites W2038307783 @default.
• W2415863453 cites W2044951291 @default.
• W2415863453 cites W2044965443 @default.
• W2415863453 cites W2050571266 @default.
• W2415863453 cites W2059560167 @default.
• W2415863453 cites W2063139303 @default.
• W2415863453 cites W2067509646 @default.
• W2415863453 cites W2073092485 @default.
• W2415863453 cites W2082534929 @default.
• W2415863453 cites W2088577648 @default.
• W2415863453 cites W2090183104 @default.
• W2415863453 cites W2098891215 @default.
• W2415863453 cites W2108147025 @default.
• W2415863453 cites W2108189527 @default.
• W2415863453 cites W2131110368 @default.
• W2415863453 cites W2134952321 @default.
• W2415863453 cites W2138551267 @default.
• W2415863453 cites W2142319725 @default.
• W2415863453 cites W2145073911 @default.
• W2415863453 cites W2145333397 @default.
• W2415863453 cites W2146629493 @default.
• W2415863453 cites W2156015715 @default.
• W2415863453 cites W2160816585 @default.
• W2415863453 cites W2169631718 @default.
• W2415863453 cites W2180665811 @default.
• W2415863453 cites W2329086168 @default.
• W2415863453 cites W2412047935 @default.
• W2415863453 cites W2520728103 @default.
• W2415863453 doi "https://doi.org/10.1371/journal.pone.0156667" @default.
• W2415863453 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4892580" @default.
• W2415863453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27257978" @default.
• W2415863453 hasPublicationYear "2016" @default.
• W2415863453 type Work @default.
• W2415863453 sameAs 2415863453 @default.
• W2415863453 citedByCount "144" @default.
• W2415863453 countsByYear W24158634532016 @default.
• W2415863453 countsByYear W24158634532017 @default.
• W2415863453 countsByYear W24158634532018 @default.
• W2415863453 countsByYear W24158634532019 @default.
• W2415863453 countsByYear W24158634532020 @default.
• W2415863453 countsByYear W24158634532021 @default.
• W2415863453 countsByYear W24158634532022 @default.
• W2415863453 countsByYear W24158634532023 @default.
• W2415863453 crossrefType "journal-article" @default.
• W2415863453 hasAuthorship W2415863453A5026252641 @default.
• W2415863453 hasAuthorship W2415863453A5041530006 @default.
• W2415863453 hasAuthorship W2415863453A5054187794 @default.
• W2415863453 hasBestOaLocation W24158634531 @default.
• W2415863453 hasConcept C121608353 @default.
• W2415863453 hasConcept C126322002 @default.
• W2415863453 hasConcept C159654299 @default.
• W2415863453 hasConcept C203014093 @default.
• W2415863453 hasConcept C2522874641 @default.
• W2415863453 hasConcept C2775940106 @default.
• W2415863453 hasConcept C2776178377 @default.
• W2415863453 hasConcept C2776185481 @default.
• W2415863453 hasConcept C2776451592 @default.
• W2415863453 hasConcept C2776461080 @default.
• W2415863453 hasConcept C2776999253 @default.
• W2415863453 hasConcept C2777382497 @default.
• W2415863453 hasConcept C2777410769 @default.
• W2415863453 hasConcept C2777701055 @default.
• W2415863453 hasConcept C2780040827 @default.
• W2415863453 hasConcept C2780593183 @default.
• W2415863453 hasConcept C2909179924 @default.
• W2415863453 hasConcept C3020491458 @default.
• W2415863453 hasConcept C71924100 @default.
• W2415863453 hasConcept C90924648 @default.
• W2415863453 hasConcept C98274493 @default.
• W2415863453 hasConceptScore W2415863453C121608353 @default.
• W2415863453 hasConceptScore W2415863453C126322002 @default.
• W2415863453 hasConceptScore W2415863453C159654299 @default.
• W2415863453 hasConceptScore W2415863453C203014093 @default.
• W2415863453 hasConceptScore W2415863453C2522874641 @default.
• W2415863453 hasConceptScore W2415863453C2775940106 @default.
• W2415863453 hasConceptScore W2415863453C2776178377 @default.
• W2415863453 hasConceptScore W2415863453C2776185481 @default.
• W2415863453 hasConceptScore W2415863453C2776451592 @default.
• W2415863453 hasConceptScore W2415863453C2776461080 @default.
• W2415863453 hasConceptScore W2415863453C2776999253 @default.
• W2415863453 hasConceptScore W2415863453C2777382497 @default.

• next